Mandatory Biological/Targeted Synthetic Disease-Modifying Antirheumatic Drugs Dose Reduction on Risk of Serious Infections in Patients with Rheumatoid Arthritis: A Nationwide Nested Case-Control Study.

Biomedicines · 2025 · PMC12730782 · PMID 41462904

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Among these patients, those who had discontinued b/tsDMARDs showed a trend toward a higher risk for a serious infection when compared with those who did not reduce the dose of b/tsDMARDs, with an adjusted OR of 2.99 (95%CI: 0.99, 9.09).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.